Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laos study aims to wipe out stomach cancer by targeting common gut bug

NCT ID NCT07340593

Disease control Sponsor: Zero Helicobacter IGAN Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study in Laos tested over 1,200 adults for H. pylori, a stomach bacteria linked to cancer. Those infected received a 14-day course of antibiotics and acid-reducing medication. The study also screened high-risk participants for early signs of stomach cancer. The goal was to see how common the infection is and whether treatment can help prevent cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
14-day triple therapy (antibiotics and acid reducer) for H. pylori infection
What this could lead to
If successful, this could show that widespread H. pylori testing and treatment reduces gastric cancer risk in high-prevalence regions.
What could go wrong
This is a completed observational and interventional study, not a randomized controlled trial. Results may not apply to other populations, and eradication therapy can fail or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,251 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study Locations 1. Luangprabang Province, Lao PDR 2. Champasak Province, Lao PDR

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Resident of Luangprabang or Champasak Province * Able to provide written informed consent Exclusion Criteria: * Severe comorbidities contraindicating screening or treatment * Allergy to medications used in triple therapy * Pregnant or breastfeeding women (if applicable)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric neoplasm Helicobacter pylori infectious disease gastric cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer screening Helicobacter eradication Helicobacter infections Prevention and control

Contacts and locations

Locations

  • National Cancer Center

    Vientiane, Capital, 0100, Laos

More trials for these conditions

Other studies related to the condition(s) this trial covers.